Daily Stock Analysis, ABMD, Abiomed Inc, priceseries

Abiomed Inc. Daily Stock Analysis
Stock Information
Open
362.02
Close
358.36
High
362.02
Low
356.69
Previous Close
362.25
Daily Price Gain
-3.89
YTD High
364.15
YTD High Date
Feb 13, 2019
YTD Low
293.66
YTD Low Date
Jan 3, 2019
YTD Price Change
48.40
YTD Gain
15.61%
52 Week High
459.75
52 Week High Date
Oct 1, 2018
52 Week Low
258.10
52 Week Low Date
Mar 1, 2018
52 Week Price Change
94.39
52 Week Gain
35.76%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Feb 15. 2017
110.62
Apr 4. 2017
124.46
33 Trading Days
12.51%
Link
LONG
Sep 6. 2017
151.61
Oct 16. 2017
171.59
28 Trading Days
13.18%
Link
LONG
Jan 2. 2018
192.49
Jan 30. 2018
228.26
19 Trading Days
18.58%
Link
LONG
May 3. 2018
335.57
May 29. 2018
378.88
17 Trading Days
12.91%
Link
Company Information
Stock Symbol
ABMD
Exchange
NasdaqGS
Company URL
http://www.abiomed.com
Company Phone
9787775410
CEO
Michael R. Minogue
Headquarters
Massachusetts
Business Address
22 CHERRY HILL DR, DANVERS, MA 01923
Sector
Equity
Industry Category
Health Services
Industry Group
Medical Appliances & Equipment
CIK
0000815094
About

ABIOMED, Inc. engages in the research, development, manufacture, and sale of cardiac support, recovery, and replacement devices. It distributes its products under the Impella brand. The company was founded in 1981 and is headquartered in Danvers, MA.

Description

ABIOMED, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; Impella CP that provides partial circulatory support using an extracorporeal bypass control unit; Impella 5.0 catheter and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; and Impella RP, a percutaneous catheter-based axial flow pump. It also manufactures and sells AB5000 circulatory support system for temporary support of acute heart failure patients in profound shock, including patients suffering from cardiogenic shock after a heart attack, post-cardiotomy cardiogenic shock, or myocarditis. In addition, the company engages in the research, development, prototyping, and the pre-serial production of a percutaneous expandable catheter pump, which enhances blood circulation from the heart with an external drive shaft. It sells its products through direct sales and clinical support personnel in the United States, Canada, Europe, and Japan. ABIOMED, Inc. was founded in 1981 and is headquartered in Danvers, Massachusetts.